Kros JM - Search Results

1

Gene expression profiles associated with treatment response in oligodendrogliomas.

French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA. French PJ, et al. Among authors: kros jm. Cancer Res. 2005 Dec 15;65(24):11335-44. doi: 10.1158/0008-5472.CAN-05-1886. Cancer Res. 2005. PMID: 16357140

2

Prognostic relevance of DNA flow cytometry in oligodendroglioma.

Kros JM, van Eden CG, Vissers CJ, Mulder AH, van der Kwast TH. Kros JM, et al. Cancer. 1992 Apr 1;69(7):1791-8. doi: 10.1002/1097-0142(19920401)69:7<1791::aid-cncr2820690722>3.0.co;2-z. Cancer. 1992. PMID: 1551064

3

Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas.

Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH. Kros JM, et al. Cancer. 1990 Sep 15;66(6):1204-12. doi: 10.1002/1097-0142(19900915)66:6<1204::aid-cncr2820660621>3.0.co;2-a. Cancer. 1990. PMID: 2205356

4

Oligodendroglioma. A comparison of two grading systems.

Kros JM, Troost D, van Eden CG, van der Werf AJ, Uylings HB. Kros JM, et al. Cancer. 1988 Jun 1;61(11):2251-9. doi: 10.1002/1097-0142(19880601)61:11<2251::aid-cncr2820611120>3.0.co;2-d. Cancer. 1988. PMID: 3365653

5

Expression of p53 in oligodendrogliomas.

Kros JM, Godschalk JJ, Krishnadath KK, Van Eden CG. Kros JM, et al. J Pathol. 1993 Dec;171(4):285-90. doi: 10.1002/path.1711710409. J Pathol. 1993. PMID: 8158458

6

Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.

Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Kros JM, et al. Cancer. 1996 Sep 1;78(5):1107-13. doi: 10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5. Cancer. 1996. PMID: 8780550

7

Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas.

Rosso SM, van Dekken H, Krishnadath KK, Alers JC, Kros JM. Rosso SM, et al. Among authors: kros jm. J Neuropathol Exp Neurol. 1997 Oct;56(10):1125-31. doi: 10.1097/00005072-199710000-00006. J Neuropathol Exp Neurol. 1997. PMID: 9329456

8

The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor.

Straathof CS, van den Bent MJ, Ma J, Schmitz PI, Kros JM, Stoter G, Vecht CJ, Schellens JH. Straathof CS, et al. Among authors: kros jm. J Neurooncol. 1998 Mar;37(1):1-8. doi: 10.1023/a:1005835212246. J Neurooncol. 1998. PMID: 9525832

9

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W. van den Bent MJ, et al. Among authors: kros jm. Neurology. 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. Neurology. 1998. PMID: 9781544

10

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.

van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J. van den Bent MJ, et al. Among authors: kros jm. Eur J Cancer. 1998 Sep;34(10):1570-4. doi: 10.1016/s0959-8049(98)00138-5. Eur J Cancer. 1998. PMID: 9893630 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

317 results

Search Page

Filters